Skip to content

Study · Animal study (in vivo) · sheep · 2012

2 results

Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor.

Rehberg S, Enkhbaatar P, Rehberg J, La E, Ferdyan N, Qi S, Wisniewski K, Traber LD, Schteingart CD, Rivière PJ, Laporte R, Traber DL

Critical care medicine1 Jun 2012Cited by 14 (Europe PMC)

PMID22488005 (opens in a new tab)PMCIDPMC7461604 (opens in a new tab)DOI10.1097/ccm.0b013e31824e0fe5 (opens in a new tab)PepBankPUB-22488005
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In sheep, the maximal vWF:Ag/Hb ratio with FE 202158 did not differ significantly from sham (9 ± 2%, p = .208).

    In plain wordsIn sheep, FE 202158 did not significantly change the clotting marker ratio compared with sham.

    Peptide
    Selepressin
    Outcome
    No significant changeMaximal vWF:Ag/Hb ratio
    Study

    sheepn = 6

    Chronically instrumented sheep
    Comparator
    Sham group
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    10 pmol·kg(-1)·min(-1) · continuous intravenous infusion · 120 minutesAs given in this study (sheep).

    Measurements

    Maximal vWF:Ag/Hb ratio
    9%
    FE 202158, percentage of baseline

    Source sentences

    Summary
    The ratio for the FE 202158 group was not statistically different from the sham group (9 ± 2%, p = .208).
    3 context sentences
    Summary · context
    Prospective, randomized, controlled laboratory experiment.
    Summary · context
    Twenty-four chronically instrumented sheep.
    Summary · context
    The von Willebrand factor antigen activity relative to hemoglobin concentration (vWF:Ag/Hb ratio) was measured at different time points during the 120-min study period.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In sheep, FE 202158 produced a lower maximal vWF:Ag/Hb ratio than arginine vasopressin (p < .005).

    In plain wordsIn sheep, FE 202158 produced a lower clotting marker ratio than arginine vasopressin.

    Peptide
    Selepressin
    Outcome
    DecreaseMaximal vWF:Ag/Hb ratio
    Study

    sheepn = 6

    Chronically instrumented sheep
    Comparator
    Arginine vasopressin
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    10 pmol·kg(-1)·min(-1) · continuous intravenous infusion · 120 minutesAs given in this study (sheep).

    Source sentences

    Summary
    Notably, maximal vWF:Ag/Hb ratio was lower in the FE 202158 than the arginine vasopressin group (p < .005).
    3 context sentences
    Summary · context
    Prospective, randomized, controlled laboratory experiment.
    Summary · context
    Twenty-four chronically instrumented sheep.
    Summary · context
    The von Willebrand factor antigen activity relative to hemoglobin concentration (vWF:Ag/Hb ratio) was measured at different time points during the 120-min study period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.